Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics And Mechanism Of Action At The Seventh Cri-enci-aacr International Cancer Immunotherapy Conference
Portfolio Pulse from Benzinga Newsdesk
Sensei Biotherapeutics presented new preclinical data at the Seventh Cri-enci-aacr International Cancer Immunotherapy Conference, reinforcing the pharmacokinetic profile, safety characteristics, and mechanism of action of SNS-101. The data from a multi-dose GLP toxicology study in cynomolgus monkeys supports the exceptional PK and safety profile of SNS-101. Mechanistic mouse data shows SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype.
September 21, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sensei Biotherapeutics' new preclinical data on SNS-101 reinforces its safety and efficacy, potentially boosting investor confidence in the company.
The new preclinical data presented by Sensei Biotherapeutics reinforces the safety and efficacy of SNS-101, which could potentially boost investor confidence in the company and its product pipeline. This could lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100